GUID - 5 en-US
GUID - 5 en-US
GUID - 5 en-US
Printed by: Maria Christina Official Date: Official as of 01-Oct-2021 Document Type: USP @2023 USPC
Do Not Distribute DOI Ref: cce10 DOI: https://doi.org/10.31003/USPNF_M58350_05_01
1
System suitability
Ofloxacin Sample: System suitability solution
Suitability requirements
Change to read: Resolution: NLT 2.0 between ofloxacin and ofloxacin
related compound A
Relative standard deviation: NMT 3.0%
Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of each impurity in the portion
of Ofloxacin taken:
C18H20FN3O4 361.37
7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 9- Result = (r U/r S) × (C S/C U) × 100
fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-
oxo-, (±)-; rU = peak response from the Sample solution
(±)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl- rS = peak response of ofloxacin from the Standard
▲
1▲ (ERR 1-Oct-2021)-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]- solution
1,4-benzoxazine-6-carboxylic acid CAS RN®: 82419-36-1; CS = concentration of USP Ofloxacin RS in the Standard
UNII: A4P49JAZ9H. solution (µg/mL)
CU = concentration of the Sample solution (µg/mL)
DEFINITION
Ofloxacin contains NLT 98.5% and NMT 101.5% of ofloxacin Acceptance criteria
(C18H20FN3O4), calculated on the dried basis. Individual impurities: NMT 0.3%. Disregard any peak less
than 0.02%.
al
IDENTIFICATION
Total impurities: NMT 0.5%
• A. SPECTROSCOPIC IDENTIFICATION TESTS á197ñ, Infrared
• LIMIT OF METHANOL AND ETHANOL
Spectroscopy: 197K
Internal standard solution: 5.6 nL/mL of n-propyl alcohol
• B. SPECTROSCOPIC IDENTIFICATION TESTS á197ñ,
in sodium hydroxide solution (1 in 100)
Ultraviolet-Visible Spectroscopy: 197U
Standard solution: 10.0 µg/mL each of methanol and
Medium: 0.1 N hydrochloric acid
Sample solution: 6.7 µg/mL in Medium
Acceptance criteria: Meets the requirements
ci dehydrated alcohol in Internal standard solution. Transfer
2 mL of this solution to a vial fitted with a septum and crimp
cap, and seal. Heat the sealed vial at 90° for 2 min, and
ASSAY shake for 6 min.
• PROCEDURE Sample solution: Transfer 40 mg of Ofloxacin to a vial fitted
ffi
Sample: 100 mg of Ofloxacin with a septum and crimp cap, add 2 mL of Internal standard
Analysis: Dissolve the Sample in 275 mL of acetic anhydride. solution, and seal the vial. Heat the sealed vial at 90° for
Titrate with 0.1 N perchloric acid VS, determining the 2 min, and shake for 6 min.
endpoint potentiometrically, using a glass–silver chloride Blank: Transfer 2 mL of Internal standard solution to a vial
electrode system (see Titrimetry á541ñ). Use the first of the fitted with a septum and crimp cap, and seal. Heat the
two inflection points. Perform a blank determination, and sealed vial at 90° for 2 min, and shake for 6 min.
O
https://online.uspnf.com/uspnf/document/1_GUID-49589C56-503E-4019-B930-9DC45304D336_5_en-US 1/2
Printed on: Wed Mar 29 2023, 08:17:02 PM(EST) Status: Currently Official on 30-Mar-2023 DocId: GUID-49589C56-503E-4019-B930-9DC45304D336_5_en-US
Printed by: Maria Christina Official Date: Official as of 01-Oct-2021 Document Type: USP @2023 USPC
Do Not Distribute DOI Ref: cce10 DOI: https://doi.org/10.31003/USPNF_M58350_05_01
2
al
carboxylic acid.
C17H18FN3O4 347.34
ci
ffi
O
https://online.uspnf.com/uspnf/document/1_GUID-49589C56-503E-4019-B930-9DC45304D336_5_en-US 2/2